Published in N Engl J Med on June 14, 2012
An in vivo platform for identifying inhibitors of protein aggregation. Nat Chem Biol (2015) 1.53
Amyloid neuropathies. Mt Sinai J Med (2012) 1.08
Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem (2013) 1.04
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica (2014) 1.00
Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol (2013) 0.93
Energy landscapes of functional proteins are inherently risky. Nat Chem Biol (2014) 0.92
An imaging and systems modeling approach to fibril breakage enables prediction of amyloid behavior. Biophys J (2013) 0.92
Systemic amyloidosis: lessons from β2-microglobulin. J Biol Chem (2015) 0.89
A new prion disease: relationship with central and peripheral amyloidoses. Nat Rev Neurol (2015) 0.87
Expanding the repertoire of amyloid polymorphs by co-polymerization of related protein precursors. J Biol Chem (2013) 0.87
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A (2014) 0.84
A simulated intermediate state for folding and aggregation provides insights into ΔN6 β2-microglobulin amyloidogenic behavior. PLoS Comput Biol (2014) 0.83
Benzalkonium chloride accelerates the formation of the amyloid fibrils of corneal dystrophy-associated peptides. J Biol Chem (2013) 0.83
Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin. J Biol Chem (2013) 0.83
Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers. J Biol Chem (2013) 0.83
β2-Microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH. PLoS One (2014) 0.81
Structure of an early native-like intermediate of β2-microglobulin amyloidogenesis. Protein Sci (2013) 0.81
D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun (2016) 0.81
C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype. PLoS One (2012) 0.80
Molecular insights into cell toxicity of a novel familial amyloidogenic variant of β2-microglobulin. J Cell Mol Med (2016) 0.79
Proteomics and mass spectrometry in the diagnosis of renal amyloidosis. Clin Kidney J (2015) 0.78
Wild type beta-2 microglobulin and DE loop mutants display a common fibrillar architecture. PLoS One (2015) 0.78
Co-fibrillogenesis of Wild-type and D76N β2-Microglobulin: THE CRUCIAL ROLE OF FIBRILLAR SEEDS. J Biol Chem (2016) 0.78
Misfolding of amyloidogenic proteins and their interactions with membranes. Biomolecules (2013) 0.77
Decoding the Structural Bases of D76N ß2-Microglobulin High Amyloidogenicity through Crystallography and Asn-Scan Mutagenesis. PLoS One (2015) 0.77
Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro. Sci Rep (2016) 0.77
Recent advances in the noninvasive strategies of cardiac amyloidosis. Heart Fail Rev (2016) 0.77
The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl) (2016) 0.76
Rational design of mutations that change the aggregation rate of a protein while maintaining its native structure and stability. Sci Rep (2016) 0.76
C-terminal sequence of amyloid-resistant type F apolipoprotein A-II inhibits amyloid fibril formation of apolipoprotein A-II in mice. Proc Natl Acad Sci U S A (2015) 0.76
A covalent homodimer probing early oligomers along amyloid aggregation. Sci Rep (2015) 0.75
Influence of heparin molecular size on the induction of C- terminal unfolding in β2-microglobulin. Mol Biol Res Commun (2016) 0.75
Structural and Thermodynamic Characteristics of Amyloidogenic Intermediates of β-2-Microglobulin. Sci Rep (2015) 0.75
Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting. Front Mol Biosci (2016) 0.75
A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo. Sci Rep (2017) 0.75
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet (2003) 4.44
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet (2005) 4.09
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr (2011) 3.32
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet (2006) 3.16
The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet Med (2011) 3.14
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood (2009) 3.00
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov (2010) 2.68
Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 2.63
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 2.62
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Neuroglobin and cytoglobin. Fresh blood for the vertebrate globin family. EMBO Rep (2002) 2.50
Plasmablastic lymphoma and related disorders. Am J Clin Pathol (2011) 2.44
New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet (2002) 2.39
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol (2012) 2.33
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Retracted A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am J Hum Genet (2011) 2.25
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem (2003) 2.15
Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest (2006) 2.14
Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH. Neurology (2014) 2.08
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
[Senile systemic amyloidosis: definition, diagnosis, why thinking about?]. Presse Med (2013) 2.00
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci (2003) 1.95
Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood (2005) 1.91
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS (2003) 1.88
Detecting false-positive signals in exome sequencing. Hum Mutat (2012) 1.87
Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87
CtBP/BARS: a dual-function protein involved in transcription co-repression and Golgi membrane fission. EMBO J (2003) 1.86
Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease. Arthritis Rheum (2005) 1.85
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (2003) 1.82
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79